In previous studies, miR-26a/b have been shown to block the G1/S transition of the cell cycle by targeting CCND2, CCNE1/2, CDK6, and EZH2 in HCC and nasopharyngeal carcinoma[15,18,32], and to restrain metastasis by suppressing the expression of IL6 in HCC[33]. Here, EZH2 is linked to hepatocellular carcinoma.